Analysis of clinical samples from Hong Kong Phase II Vaccine Study
Research type
Research Study
Full title
Analysis of samples from a Phase 2 clinical trial of MVA-EBNA1/LMP2 in Hong Kong
IRAS ID
159061
Contact name
Graham S Taylor
Contact email
Sponsor organisation
University of Birmingham
Clinicaltrials.gov Identifier
Phase 2 Protocol PWH version 3.2 27 sep 2012, Protocol for trial supplying samples
Research summary
MVA-EBNA1/LMP2 is a therapeutic cancer vaccine designed to boost the anti-cancer immune response in patients with Epstein-Barr virus (EBV) positive Cancer. The vaccine has been tested in phase 1A trials and is now undergoing testing in patients in a Phase 2 trial in Hong Kong. All ethical approvals for the Hong Kong trial are in place.
This ethical application is made solely to allow us (University of Birmingham, UK) to receive the samples from this trial in order for us to analyse the immune response stimulated by the vaccine in the patients. Blood samples taken and stored in Hong Kong will be sent to our laboratory, where we will measure the size and characteristics of the immune response.
The results will give us a better idea of how the vaccine works so we can improve its use and advance its development into a licenced medicine.
REC name
South Central - Oxford C Research Ethics Committee
REC reference
14/SC/1178
Date of REC Opinion
28 Jul 2014
REC opinion
Favourable Opinion